In November 2021, Arkansas enacted a law, known as Act 1103, that prohibited drugmakers from placing restrictions on 340B contract pharmacies and child sites. The Pharmaceutical Research and Manufacturers of America (PhRMA) immediately filed suit to block implementation of Act 1103, delaying enforcement of the law for nearly 2 years. However, on March 12, 2024, the U.S. Court of Appeals for the Eighth Circuit rejected PhRMA’s arguments and ruled Act 1103 is valid and enforceable. In the podcast, we talk about the implications of the ruling for the broader 340B program and covered entities nationwide.
Kyle Robb, PharmD is director of State Policy & Advocacy at ASHP. Kyle supports ASHP members and State Affiliates as they seek to advance the practice of pharmacy through engagement with state government.
Prior to working at ASHP, Kyle was a pharmacist at the University of Virginia Health System and a health policy fellow on the staff of the U.S. Senate Committee on Health, Education, Labor & Pensions. 
Tom Kraus, JD, MHS serves as the vice president of government relations for ASHP. Kraus previously served as the deputy staff director of health on the U.S. Senate Committee on Health, Education, Labor and Pensions under Senators Edward Kennedy and Tom Harkin, where he was instrumental in the passage of key legislation, including Food and Drug Administration (FDA) drug and food safety reforms and user fee legislation, the American Recovery and Reinvestment Act, and the Affordable Care Act. Following his time on Capitol Hill, he joined the FDA, where he served as Chief of Staff and Associate FDA Commissioner for Legislation. 
